(NEU) Neuca S.A. - Ratings and Ratios

NEUCA S.A. (WAR:NEU) is a leading player in Polands pharmaceutical sector, specializing in the wholesale distribution of medicines and related healthcare products. The company operates through multiple segments, including Wholesale Distribution of Medicines, Manufacture of Pharmaceuticals, Medical Operator, Clinical Trials, and Insurance Activities. Its product portfolio includes prescription drugs (Rx), over-the-counter (OTC) medicines, dietary supplements, medical devices, dermocosmetics, hygiene products, personal protective equipment (PPE), and diagnostic and dressing materials. These products are marketed under well-known brands such as Swiat Zdrowia, APTEO, GENOPTIM, CERA+ Solutions, and Kic Kic, catering to pharmacists, medical professionals, and patients.

NEUCA S.A. also provides a wide range of medical care services, including prevention, diagnostics, treatment, and complementary services. Its insurance activities encompass health insurance products, financing services like subscriptions, occupational medicine, and preventive programs. Additionally, the company offers TPA (Third-Party Administrator) services, remote consultations, stationary visits, diagnostic tests, and occupational medicine services. It operates a medical helpline, runs medical facilities, and offers an e-commerce platform, apteline.pl, for online medical orders. NEUCA further engages in clinical trials, advertising, and marketing services for pharmaceutical entities, as well as logistics support for pharmaceutical manufacturers.

Originally established in 1990 as Torfarm SA, the company rebranded as NEUCA S.A. in April 2010. Headquartered in Torun, Poland, NEUCA has grown into a diversified healthcare conglomerate with a strong presence in Polands pharmaceutical and medical services market. Its operations are supported by a robust infrastructure and a focus on innovation, making it a key player in the regions healthcare ecosystem.

Ticker Symbol: NEU
Exchange: WAR
Type: common stock
Country Origin: Poland
GICS Sub Industry: Drug Retail

Average Volume 20d: 1470
Last Price: 687.00
SMA 20: 701.05
SMA 50: 770.54
SMA 200: 819.09
ATR: 21.37

Market Cap: 3093.62M PLN
P/E: 19.12
P/E Forward: None
P/B: 2.81
P/S: 0.25
RoE: 14.68

3-Month Forecast:
Based on and , NEUCA S.A. is expected to experience moderate price volatility. The stocks SMA 20, SMA 50, and SMA 200 indicate a potential bearish trend, with the last price below these moving averages. The ATR of 21.37 suggests moderate volatility. On the fundamental side, the P/E ratio of 19.12 reflects a premium valuation, while the P/S ratio of 0.25 indicates undervaluation relative to sales. The RoE of 14.68% highlights strong profitability. Overall, the stock may consolidate in the near term, with potential downside risks driven by high valuation multiples and technical weakness.